S Namba — Page 7 | PubMed Health

PubMedDate not supplied

A case of pyrazinamide-associated myoglobinuric renal failure.

A 50-year-old man developed myoglobinuric renal failure after taking pyrazinamide. Both serum and urine myoglobin levels were elevated and tubulo-interstitial nephropathy was demonstrated on renal biopsy. After pyrazinamide was discontinued, the myoglobin concentrations were normalized and his renal function ameliorated. The rhabdomyolysis was considered to be caused by pyrazinamide. To our knowledge, this is the first reported case of rhabdomyolysis associated with pyrazinamide.

Acute Kidney Injury↗

PubMedDate not supplied

Clinical application of low calcium peritoneal dialysate.

Low calcium dialysate (LCa) with calcium levels of 2.3 mEq/L was prepared for peritoneal dialysis, and its equilibration was compared with those of conventional dialysates with calcium contents of 3.5 mEq/L and 4.0 mEq/L. The variation in dialysate to plasma concentration ratios of total calcium of conventional dialysates was positive; that of LCa was negative. Mass transfer of calcium per day was positive and normal for calciums of 4.0 mEq/L (31 +/- 51 mg/day) and 3.5 mEq/L (-37 +/- 40 mg/day), compared with a negative balance for LCa (-157 +/- 26 mg/day). The LCa was used in six patients over 6 months. The doses of calcium carbonate and vitamin D also were increased from 1.2 +/- 1.5 to 5.4 +/- 3.3 g/day (p less than 0.05) and from 0.17 +/- 0.2 to 0.38 +/- 0.47 micrograms/day, respectively. Aluminum gel was discontinued. Low calcium dialysate may become the standard dialysate for stable continuous ambulatory peritoneal dialysis patients.

Adult↗